MICRO-MECHANICAL PUMP FOR NEXT GENERATION INSULIN DELIVERY SYSTEMS

Introduction

PRISMA is a revolutionary thin-film micropump realized with novel ceria-based oxides actuating materials in the frame of the FET-OPEN BioWings project. It can be used as an innovative pumping system in wearable insulin delivery devices for the treatment of diabetes.

Pain Points Addressed

The integration of the PRISMA micropump in insulin patch pumps addresses the three most important pain points that still keep the vast majority of diabetic patients away from this life-saving treatment:

1. Size: The micropump is more than two orders of magnitude smaller than state of the art.
2. Drug Delivery Accuracy: Higher drug delivery accuracy within the ±5% range ensures the highest therapeutic efficacy.
3. Energy Consumption: There is a drastic reduction in energy consumption.

Long-Term Vision

Besides the short-term vision to realize extremely compact and accurate patch pumps, the long-term goal is to allow the realization of multi-drug delivery systems, making real the much-lauded multi-hormone treatment.

Project Objective

The main objective of this project is to validate the pump and its manufacturing process in a real operating environment. This will prove to system integrators that all specifications are consistently met, paving the way for post-project system integration and clinical validation.

Future Prospects

This validation will pave the way for the launch of a startup company that will take care of the final steps of the development roadmap. The company will establish long-term cooperation agreements with prominent medical device manufacturers for the integration of PRISMA in next-generation single and multi-hormone smart patches.